CONMED (NYSE:CNMD) Shares Gap Down After Analyst Downgrade

Shares of CONMED Co. (NYSE:CNMD) gapped down before the market opened on Thursday after JPMorgan Chase & Co. lowered their price target on the stock from $115.00 to $75.00. The stock had previously closed at $70.01, but opened at $63.37. JPMorgan Chase & Co. currently has an overweight rating on the stock. CONMED shares last traded at $64.35, with a volume of 469,350 shares changing hands.

Several other equities analysts also recently weighed in on the company. Wells Fargo & Company reduced their price target on CONMED from $98.00 to $77.00 and set an “equal weight” rating for the company in a report on Thursday. Piper Sandler cut their price objective on shares of CONMED from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Needham & Company LLC decreased their target price on shares of CONMED from $129.00 to $107.00 and set a “buy” rating for the company in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, CONMED currently has a consensus rating of “Moderate Buy” and an average price target of $107.86.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. GAMMA Investing LLC purchased a new position in shares of CONMED in the fourth quarter valued at about $40,000. Principal Securities Inc. purchased a new position in CONMED in the 4th quarter worth approximately $46,000. Headlands Technologies LLC bought a new position in CONMED in the 3rd quarter worth approximately $64,000. AdvisorNet Financial Inc grew its holdings in CONMED by 70.6% during the 1st quarter. AdvisorNet Financial Inc now owns 1,800 shares of the company’s stock valued at $144,000 after buying an additional 745 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its position in shares of CONMED by 44.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,631 shares of the company’s stock valued at $179,000 after buying an additional 500 shares during the last quarter.

CONMED Stock Performance

The company has a debt-to-equity ratio of 1.17, a current ratio of 1.98 and a quick ratio of 0.96. The firm’s 50-day moving average price is $78.36 and its 200-day moving average price is $93.67. The stock has a market cap of $1.91 billion, a P/E ratio of 30.34, a PEG ratio of 0.65 and a beta of 1.33.

CONMED (NYSE:CNMD) last posted its earnings results on Wednesday, April 24th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The company had revenue of $312.27 million for the quarter, compared to the consensus estimate of $307.06 million. CONMED had a return on equity of 13.69% and a net margin of 5.18%. Sell-side analysts expect that CONMED Co. will post 4.34 earnings per share for the current fiscal year.

CONMED Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 5th. Investors of record on Friday, March 15th were given a $0.20 dividend. The ex-dividend date was Thursday, March 14th. This represents a $0.80 annualized dividend and a yield of 1.29%. CONMED’s dividend payout ratio is currently 39.22%.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.